SH3051
/ Nanjing Sanhome Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 09, 2020
A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=45; Recruiting; Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1